Toan T. Nguyen

TL;DR: BCRL is a sequelae of multimodal breast cancer treatment and risk is multifactorial, higher in patients receiving chemotherapy, radiation, ALND, more advanced disease stage, and higher body mass index.

TL;DR: Evaluated breast cancer patients with a percutaneous biopsy-positive axillary lymph node, clipped at the time of diagnosis, who underwent NAC followed by surgery found that the clipped node can be identified by preoperative CT, routine SLN surgery, intraoperative ultrasound, or palpation.

TL;DR: A significant shift in axillary surgery for cN1 breast cancer patients treated with NAC is observed, with increasing use of SLN surgery to assess nodal treatment response, and decreasing use of ALND.

TL;DR: In this article, the authors discuss the impact of the COVID-19 pandemic on cancer clinical trials and changes at the local, cooperative group, and national level at the cooperative group level.

TL;DR: Adjuvant HT use in ER+ DCIS has increased over time, with the highest rates in patients treated with BCS and radiation, and higher use of HT was associated with more recent calendar year, age between 40 and 80 years, female sex, positive progesterone receptor status, and radiation use.